Nitazoxanide for COVID-19

Adding first major clinical trial

philipn authored on Nov. 3, 2020, 2:04 a.m.

Review changes View this version of the page

You can also use the and keys

~~Deletions are marked like this~~	Additions are marked like this
Nitazoxanide shows anti-SARS-CoV-2 activity in Vero E6 cells. From "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Photo CC-BY Wang, M., Cao, R., Zhang, L. et al. Nitazoxanide, a broad-spectrum antiparasitic, has been proposed as a possible COVID-19 therapeutic. In vitro anti-SARS-CoV-2 activity Nitazoxanide shows anti-SARS-CoV-2 activity in Vero E6 cells and has broad activity against a range of viruses. However, activity in Vero cells does not appear sufficient to establish effiacy in vivo, as hydroxychloroquine/chloroquine have strong anti-SARS-CoV-2 activity in Vero cells but fail in vivo, perhaps due to differences in TMPRSS2 expression. Nitazoxnide may also "[potentiate] the production of type 1 interferons (alpha and beta) produced by the host’s fibroblasts," a possible mechanism of benefit in COVID-19. Nitazoxanide for COVID-19 research reviews "Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?" "Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19" "Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis" See also COVID-19 therapeutics	Nitazoxanide shows anti-SARS-CoV-2 activity in Vero E6 cells. From "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Photo CC-BY Wang, M., Cao, R., Zhang, L. et al. Nitazoxanide, a broad-spectrum antiparasitic, has been proposed as a possible COVID-19 therapeutic. In vitro anti-SARS-CoV-2 activity Nitazoxanide shows anti-SARS-CoV-2 activity in Vero E6 cells and has broad activity against a range of viruses. However, activity in Vero cells does not appear sufficient to establish effiacy in vivo, as hydroxychloroquine/chloroquine have strong anti-SARS-CoV-2 activity in Vero cells but fail in vivo, perhaps due to differences in TMPRSS2 expression. Nitazoxnide may also "[potentiate] the production of type 1 interferons (alpha and beta) produced by the host’s fibroblasts," a possible mechanism of benefit in COVID-19. Clinical trials for COVID-19 On October 23, 2020 a randomized, placebo-controlled trial of nitazoxanide in Brazil reported results: In patients with mild Covid-19, symptom resolution did not differ between the nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly. --Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial Critiques of this trial include this twitter thread by Cardiologist Marcio S Bittencourt and that the drug may have been underdosed. Nitazoxanide for COVID-19 research reviews "Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?" "Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19" "Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis" See also COVID-19 therapeutics

~~Deletions are marked like this~~

Additions are marked like this

Nitazoxanide shows anti-SARS-CoV-2 activity in Vero E6 cells. From "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro". Photo CC-BY Wang, M., Cao, R., Zhang, L. et al.

Nitazoxanide, a broad-spectrum antiparasitic, has been proposed as a possible COVID-19 therapeutic.

In vitro anti-SARS-CoV-2 activity

Nitazoxanide shows anti-SARS-CoV-2 activity in Vero E6 cells and has broad activity against a range of viruses. However, activity in Vero cells does not appear sufficient to establish effiacy in vivo, as hydroxychloroquine/chloroquine have strong anti-SARS-CoV-2 activity in Vero cells but fail in vivo, perhaps due to differences in TMPRSS2 expression.

Nitazoxnide may also "[potentiate] the production of type 1 interferons (alpha and beta) produced by the host’s fibroblasts," a possible mechanism of benefit in COVID-19.

Nitazoxanide for COVID-19 research reviews

In vitro anti-SARS-CoV-2 activity

Nitazoxnide may also "[potentiate] the production of type 1 interferons (alpha and beta) produced by the host’s fibroblasts," a possible mechanism of benefit in COVID-19.

Clinical trials for COVID-19

On October 23, 2020 a randomized, placebo-controlled trial of nitazoxanide in Brazil reported results:

In patients with mild Covid-19, symptom resolution did not differ between the nitazoxanide and placebo groups after 5 days of therapy. However, early nitazoxanide therapy was safe and reduced viral load significantly. --Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial

Critiques of this trial include this twitter thread by Cardiologist Marcio S Bittencourt and that the drug may have been underdosed.

dronico / Nitazoxanide for COVID-19 0d7ce492e432858c4c428efb7585e91dc1c0cb5c

In vitro anti-SARS-CoV-2 activity

Nitazoxanide for COVID-19 research reviews

See also

In vitro anti-SARS-CoV-2 activity

Clinical trials for COVID-19

Nitazoxanide for COVID-19 research reviews

See also